Related Experiment Video
Updated: Aug 2, 2026
06:40
Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
Published on: May 22, 2018
Gene interventions in the beta-adrenergic system for treating heart failure
1Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Seminars in Thoracic and Cardiovascular Surgery
|September 16, 2003
Summary
Chronic heart failure (HF) deaths are rising despite advances in cardiovascular disease treatment. Manipulating the myocardial beta-adrenergic receptor (betaAR) system offers potential for novel HF therapies.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- Cardiovascular disease remains a leading cause of death, with mortality rates significantly reduced by prevention and treatment.
- Despite overall progress, chronic heart failure (HF) mortality continues to increase, highlighting the need for advanced therapies, especially for end-stage cases.
- The myocardial beta-adrenergic receptor (betaAR) system plays a crucial role in both chronic and acute cardiac dysfunction.
Purpose of the Study:
- To explore the significance of the myocardial beta-adrenergic receptor (betaAR) system in heart failure.
- To investigate the potential of genetically manipulating betaAR signaling for therapeutic benefit in HF.
- To assess the possibility of improving existing HF treatment strategies through targeted betaAR modulation.
Main Methods:
- This study focuses on the theoretical and potential applications of genetic manipulation of the beta-adrenergic receptor (betaAR) system.
- The research involves analyzing the role of betaAR signal transduction pathways in the context of heart failure.
- Investigational approaches may include molecular modeling, genetic studies, and pharmacological interventions targeting betaAR.
Main Results:
- The beta-adrenergic receptor (betaAR) system is integral to cardiac function and is implicated in the pathophysiology of heart failure.
- Altering betaAR signal transduction is a key strategy in current HF pharmacotherapy.
- Genetic manipulation of cardiac betaAR signaling presents a promising avenue for developing new therapeutic approaches.
Conclusions:
- The myocardial beta-adrenergic receptor (betaAR) system is a critical target for understanding and treating heart failure.
- Genetic modulation of betaAR signaling holds potential for providing unique inotropic support.
- Further research into manipulating betaAR signaling could lead to improved therapeutic strategies for chronic and end-stage heart failure.
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...